Evaluation of the Sensory Attributes of Olopatadine 0.6% and Azelastine 137mcg Nasal Sprays in Patients w/Allergic Rhinitis
NCT00772304
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
102
Enrollment
INDUSTRY
Sponsor class
Conditions
Allergic Rhinitis
Interventions
DRUG:
Olopatadine 0.6% / Azelastine 137 mcg
Sponsor
Alcon Research